-+ 0.00%
-+ 0.00%
-+ 0.00%

Keros Therapeutics Authorizes New $5 Million Share Buyback Program

PUBT·11/16/2026 21:01:52
Listen to the news
Keros Therapeutics Authorizes New $5 Million Share Buyback Program
  • Keros Therapeutics authorized a new $5 million common stock buyback program.
  • The authorization follows receipt of a $20 million development milestone payment under its elritercept license agreement with Takeda Pharmaceuticals U.S.A.
  • The payment was triggered by dosing the first patient in the ELRiSE MF clinical trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611161601PRIMZONEFULLFEED9878789) on November 16, 2026, and is solely responsible for the information contained therein.